Design of an integrated analysis that includes genomic profiling, immunophenotyping, and outcome evaluation of patients with BCR-ABL1− B-ALL treated in the UKALLXII/ECOG-ACRIN E2993 trial.7 Of the patients previously classified in the protocol as high risk (based on WBC count and age), 39.4% were restratified as molecular standard risk (21.2%) or intermediate risk (18.2%). Professional illustration by Patrick Lane, ScEYEnce Studios.